Abebaw M Yohannes1, W Chen2, Ana M Moga3, I Leroi4, Martin J Connolly5. 1. Manchester Metropolitan University, Manchester, United Kingdom. Electronic address: A.yohannes@mmu.ac.uk. 2. University of British Columbia, Vancouver, Canada. 3. McGill University, Montreal, Canada. 4. The University of Manchester, Manchester, United Kingdom. 5. The University of Auckland and Waitemata District Health Board, Auckland, New Zealand.
Abstract
BACKGROUND: Cognitive impairment is common in people living with chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF); however, accurate estimates of prevalence are lacking. To date, there are no meta-analyses that have specifically investigated prevalence of mild cognitive impairment (MCI) in this particular population. Our aim was to undertake a systematic review and apply meta-analytic methods to estimate the prevalence of MCI and any cognitive impairment (ACI) in people with COPD and CHF. METHODS: We identified relevant studies for COPD and CHF by searching the published literature from inception to February 2016 using the MEDLINE and Web of Science databases. Studies were included if they documented the prevalence of MCI and/or cognitive impairment for COPD and CHF patients without dementia. RESULTS: Seventeen studies including people with CHF (n = 29,456) and 14 studies including people with COPD (n = 23,116) were included. The pooled mean age for COPD was 66.3 years and for CHF, 75.6 years. The pooled prevalence of MCI in the COPD was 25% (95% CI: 23%, 42%) and ACI, 32% (95% CI: 18%, 38%). Correspondingly, the pooled prevalence of MCI in those with CHF was 32% (95% CI: 22%, 43%) and ACI, 31% (95% CI: 23%, 40%). CONCLUSIONS: One in 4 people with COPD and 1 in 3 people with CHF had MCI, respectively. The overall prevalence of ACI for COPD was 32% and for CHF, 31%. Future work should consider ways of detecting, managing, or improving cognitive function and other cognition-related outcomes in this group of people.
BACKGROUND:Cognitive impairment is common in people living with chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF); however, accurate estimates of prevalence are lacking. To date, there are no meta-analyses that have specifically investigated prevalence of mild cognitive impairment (MCI) in this particular population. Our aim was to undertake a systematic review and apply meta-analytic methods to estimate the prevalence of MCI and any cognitive impairment (ACI) in people with COPD and CHF. METHODS: We identified relevant studies for COPD and CHF by searching the published literature from inception to February 2016 using the MEDLINE and Web of Science databases. Studies were included if they documented the prevalence of MCI and/or cognitive impairment for COPD and CHFpatients without dementia. RESULTS: Seventeen studies including people with CHF (n = 29,456) and 14 studies including people with COPD (n = 23,116) were included. The pooled mean age for COPD was 66.3 years and for CHF, 75.6 years. The pooled prevalence of MCI in the COPD was 25% (95% CI: 23%, 42%) and ACI, 32% (95% CI: 18%, 38%). Correspondingly, the pooled prevalence of MCI in those with CHF was 32% (95% CI: 22%, 43%) and ACI, 31% (95% CI: 23%, 40%). CONCLUSIONS: One in 4 people with COPD and 1 in 3 people with CHF had MCI, respectively. The overall prevalence of ACI for COPD was 32% and for CHF, 31%. Future work should consider ways of detecting, managing, or improving cognitive function and other cognition-related outcomes in this group of people.
Authors: Amit D Parulekar; Carlos Martinez; Chu-Lin Tsai; Nicholas Locantore; Mustafa Atik; Abebaw M Yohannes; Christina C Kao; Hassan Al-Azzawi; Ali Mohsin; Robert A Wise; Marilyn G Foreman; Dawn L Demeo; Elizabeth A Regan; Barry J Make; Aladin M Boriek; Laura E Wiener; Nicola A Hanania Journal: J Am Med Dir Assoc Date: 2017-12-01 Impact factor: 4.669
Authors: Mareye Voortman; Jolanda De Vries; Celine M R Hendriks; Marjon D P Elfferich; Petal A H M Wijnen; Marjolein Drent Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2019-05-01 Impact factor: 0.670
Authors: Daniel B Kramer; Daniel Habtemariam; Yaw Adjei-Poku; Michelle Samuel; Diane Engorn; Matthew R Reynolds; Susan L Mitchell Journal: J Am Heart Assoc Date: 2017-09-22 Impact factor: 5.501
Authors: Cindy V Leiton; Elyssa Chen; Alissa Cutrone; Kristy Conn; Kennelia Mellanson; Dania M Malik; Michael Klingener; Ryan Lamm; Michael Cutrone; John Petrie; Joher Sheikh; Adriana DiBua; Betsy Cohen; Thomas F Floyd Journal: Hypoxia (Auckl) Date: 2018-11-08